Celltrion ‘Omriklo’, “Confirm equivalent to the original clinical book of the 40 weeks”

Based on the provided breaking news content, here’s a breakdown and analysis:

1. News Headline:

   • Global clinical trials of phase III tracking data disclosure… Validation and safetyCruise of 6 trillion won in global markets such as the US and Europe.
   • Celltrion biosimilar ‘CT-P39’ (Omriklo) data disclosed in a renowned journal.

2. Key Points:

   • Journal: Clinical & Translational Allergy (CTA), an official journal of the European Allergic Clinical Immunology Society.
   • Drug: Omriklo, a biosimilar of antibody biopharmaceuticals developed by Genentech and Novartis.
   • Study: Published results of a phase III trial involving 619 chronic idiopathic urticaria patients, confirming the drug’s effectiveness and safety.
   • Sales: Jalore (the original drug) recorded about 6 trillion won (approx. USD 5 billion) in global sales last year.
   • Approval: Omriklo is the first biosimilar licensed in several major global markets, having obtained approvals in Korea, the US, Europe, the UK, and Canada.
   • US Market:celltrion biosimilar will be recognized as ‘Interchangeable’ biosimilars in the US, allowing pharmacies to substitute it for the prescribed original drug.
   • Company Plan: Celltrion aims to capture the global Omalizumab (anti-IgE therapy) market with this validation and accelerate its market presence.

3. Implications:

   • The publication of the phase III trial results in a reputed journal like CTA validates the drug’s efficacy and safety, reinforcing Celltrion’s competitiveness.
   • Obtaining interchangeable biosimilar status in the US allows for pharmacy-level substitution, potentially increasing market share and sales.
   • A strong market position in the anti-IgE therapy segment could lead to significant revenue growth for Celltrion.

4. Impact on Global Markets:

   • Celltrion’s successful validation and approvals in major global markets position it as a strong contender in the biosimilar market.
   • Increased market share and sales potential in regions like the US, Europe, and Asia.
   • Enhanced perception of South Korean biosimilar companies globally.
5. Future Outlook:
   • With successful clinical trials and approvals, Celltrion may focus on expanding Omriklo’s presence in other global markets and developing new biosimilars.
   • Increased competition in the biosimilar market may also lead to more clinical trials and validation efforts from competitors.